News
MEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its ...
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 20, 2025 /PRNewswire/ -- Equity Insider News Commentary - The World Economic ...
From surgical precision tools to real-time diagnostics, brain-responsive stimulation, and multi-disease detection systems, AI ...
May 16 (UPI) --Novo Nordisk announced Friday that CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday that Jorgensen will continue as CEO ...
Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Novo Nordisk ...
Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive ...
Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time high in the markets. Despite being the first to ...
Share on Pinterest A Wegovy weight loss pill from Novo Nordisk is forthcoming, providing an alternative to injectable GLP-1 drugs. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images Federal ...
The U.S. Food and Drug Administration has accepted Novo Nordisk’s application for an oral version of its blockbuster weight loss drug Wegovy. The Danish drugmaker – which has its U.S ...
Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...
Novo Nordisk has submitted an "Ozempic pill" to the FDA for approval. The new pill will probably be popular (if approved). However, making it will require Novo Nordisk to ramp up semaglutide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results